---
title: Korean Red Ginseng and Metabolic Syndrome
nct_id: NCT00976274
overall_status: COMPLETED
phase: NA
sponsor: The Korean Society of Ginseng
study_type: INTERVENTIONAL
primary_condition: Metabolic Syndrome
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00976274.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00976274"
ct_last_update_post_date: 2012-02-27
last_seen_at: "2026-05-12T06:52:57.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Korean Red Ginseng and Metabolic Syndrome

**Official Title:** Effects of Korean Red Ginseng on Cardiovascular Risks in Subjects With Metabolic Syndrome

**NCT ID:** [NCT00976274](https://clinicaltrials.gov/study/NCT00976274)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** The Korean Society of Ginseng
- **Conditions:** Metabolic Syndrome
- **Start Date:** 2009-08
- **Completion Date:** 2011-01
- **CT.gov Last Update:** 2012-02-27

## Brief Summary

Five factor consisting of Metabolic syndrome is closely linked by insulin resistance. Until now, several studies have been performed about effects of Korea red ginseng on hypertension, diabetes, and hyperlipidemia, but not metabolic syndrome.

The investigators hypothesize that Korean red ginseng could improve each constituents of metabolic syndrome, arterial stiffness, and inflammatory markers.

The aim of this study is to determine effects of Korean red ginseng on cardiovascular risks in subjects with metabolic syndrome.

## Detailed Description

The details of study objective are followed by these:

* comparison of blood pressure before and after Korean red ginseng administration
* comparison of metabolic indicator before and after Korean red ginseng administration
* comparison of oxidative stress and inflammatory markers before and after Korean red ginseng administration
* comparison of arterial stiffness before and after Korean red ginseng administration

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:(three or more of following five factors)

* waist circumference(male: more than 90cm, female: more than 80cm)
* blood pressure(systolic: more than 130mmHg, diastolic: more than 85mmHg)
* fasting plasma glucose: more than 100mg/dL
* fasting triglycerides: more than 150mg/dL
* High-density lipoprotein(HDL)-cholesterol(male: less than 40mg/dL, female: less than 50mg/dL)

Exclusion Criteria: (any one of following factors)

* uncontrolled blood pressure(systolic: more than 160mmHg, diastolic: more than 100mmHg) or subjects taking blood pressure lowering drug
* Type 2 diabetes patients or fasting plasma glucose more than 126mg/dL
* triglyceride more than 400mg/dL, total cholesterol more than 250mg/dL
* subjects taking antilipidemic drug
* past history of coronary heart disease or cerebrovascular disease
```

## Arms

- **starch capsule** (PLACEBO_COMPARATOR)
- **Korea red ginseng** (EXPERIMENTAL)

## Interventions

- **Korean red ginseng** (DIETARY_SUPPLEMENT) — 5 capsules (300 mg/capsule) three times everyday for 12 weeks
- **starch** (DIETARY_SUPPLEMENT) — 5 capsules three times everyday for 12 weeks

## Primary Outcomes

- **Change in the Pre- and Post-treatment Systolic Blood Pressure** _(time frame: baseline and 12 weeks)_

## Secondary Outcomes

- **Change in the Pre- and Post-treatment Oxidized Low-densty Lipoprotein(LDL)** _(time frame: baseline and 12 weeks)_

## Locations (1)

- Yonsei Univeristy College of Medicine, Gangnam Severance Hospital, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `locations.yonsei univeristy college of medicine, gangnam severance hospital|seoul||south korea` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00976274.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00976274*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*